RxDoctor Payments Data

Vivian Hobayan, MD

Rheumatology · Lima, OHNPI 1790852333

Payments from drug & device makers

$1,523in general payments, 2019–2025

Across 44 payments — averaging $34.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$557
  • AbbVie$521
  • Sobi, Inc$145
  • UCB, Inc.$144
  • GSK$109
  • E.r. Squibb & Sons, L.L.C.$27
  • plus $20 from 1 others

What the payments were for

  • Food & beverage$1,04669%
  • Education$47731%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson7$557
AbbVie31$521
Sobi, Inc1$145
UCB, Inc.1$144
GSK1$109
E.r. Squibb & Sons, L.L.C.2$27
Amgen1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,523 in reported general payments places this provider in the 50th percentile of 255 rheumatology providers in Ohio.

See all rheumatology providers in Ohio

Medicare billing

Part B allowed, 2024
$2,485,550
Medicare patients
557
Services billed
109,361

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept107$815,416
EnbrelEtanercept25$202,075
RinvoqUpadacitinib21$131,773
Cosentyx Sensoready (2 Pens)Secukinumab12$89,148
Orencia ClickjectAbatacept15$84,203
Hydroxychloroquine Sulfate1,205$47,353
ProliaDenosumab19$32,324
MethotrexateMethotrexate Sodium877$22,522
Prednisone859$8,500
Risedronate Sodium98$8,320
Leflunomide131$7,190
Mycophenolate Mofetil56$5,797
Sulfasalazine DrSulfasalazine177$4,985
Sulfasalazine214$4,636
Colchicine59$4,228

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel, Prolia$20$234,39944 claims
AbbVieRinvoq$521$131,77321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 255 rheumatology providers in Ohio.

Other rheumatology in Lima

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →